Advertisement

Archives of Pharmacal Research

, Volume 39, Issue 3, pp 398–408 | Cite as

Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro

  • Sae-Kwang Ku
  • Eun-Kyung Yoon
  • Wonhwa Lee
  • Sinae Kwon
  • Taeho Lee
  • Jong-Sup BaeEmail author
Research Article

Abstract

Pelargonidin is a well-known red pigment found in plants, and has been reported as having important biological activities that are potentially beneficial for human health. However, the possible roles of pelargonidin as an anticoagulant and the underlying mechanism have not yet been elucidated. We tested the effect of pelargonidin and its glucoside-conjugated form, pelargonidin-3-glucoside, on the clotting times, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the activities and productions of thrombin and activated factor X (FXa). Furthermore, the effects of pelargonidin on the fibrin polymerization, platelet aggregation, and the ratio of plasminogen activator inhibitor-1 (PAI-1) to tissue plasminogen activator were determined. Pelargonidin, but not pelargonidin-3-glucoside, prolonged the aPTT and PT, and inhibited the activity and production of thrombin and FXa in human umbilical vein endothelial cells. Furthermore, pelargonidin inhibited thrombin-catalyzed fibrin polymerization and platelet aggregation and elicited anticoagulant effects in mice. In addition, pelargonidin significantly reduced PAI-1 to t-PA ratio. Collectively, these results indicate that the anthocyanin pelargonidin possesses antithrombotic activity, and can be beneficial in preventing thrombus formation, thus improving blood circulation.

Keywords

Pelargonidin Anticoagulation Antiplatelets Fibrinolysis Endothelium 

Notes

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2012R1A5A2A42671316) and a grant (PJ010840) from the Agenda program, Rural Development Administration.

Compliance with ethical standards

Conflict of interes

The authors have no conflicts of interest to declare.

References

  1. Bae JS, Lee W, Nam JO, Kim JE, Kim SW, Kim IS (2014) Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses. Am J Respir Crit Care Med 189:779–786CrossRefPubMedGoogle Scholar
  2. Bauer KA (2013) Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program 2013:464–470CrossRefPubMedGoogle Scholar
  3. Beecher GR (2003) Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133:3248S–3254SPubMedGoogle Scholar
  4. Beretz A, Cazenave JP, Anton R (1982) Inhibition of aggregation and secretion of human platelets by quercetin and other flavonoids: structure-activity relationships. Agents Actions 12:382–387CrossRefPubMedGoogle Scholar
  5. Dahlback B (2000) Blood coagulation. Lancet 355:1627–1632CrossRefPubMedGoogle Scholar
  6. Davie EW (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74:1–6PubMedGoogle Scholar
  7. Davie EW, Fujikawa K, Kisiel W (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30:10363–10370CrossRefPubMedGoogle Scholar
  8. Despotis GJ, Gravlee G, Filos K, Levy J (1999) Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology 91:1122–1151CrossRefPubMedGoogle Scholar
  9. Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, Vidal JM, van de Vorstenbosch C (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15–23CrossRefPubMedGoogle Scholar
  10. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417–430CrossRefPubMedGoogle Scholar
  11. Fares A (2013) Winter cardiovascular diseases phenomenon. N Am J Med Sci 5:266–279CrossRefPubMedPubMedCentralGoogle Scholar
  12. Franke B, Akkerman JW, Bos JL (1997) Rapid Ca2 + -mediated activation of Rap1 in human platelets. EMBO J 16:252–259CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fukumoto LR, Mazza G (2000) Assessing antioxidant and prooxidant activities of phenolic compounds. J Agric Food Chem 48:3597–3604CrossRefPubMedGoogle Scholar
  14. Furie B, Furie BC (2005) Thrombus formation in vivo. J Clin Invest 115:3355–3362CrossRefPubMedPubMedCentralGoogle Scholar
  15. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LV (2007) Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 5:336–346CrossRefPubMedGoogle Scholar
  16. Hamaguchi E, Takamura T, Shimizu A, Nagai Y (2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 307:987–994CrossRefPubMedGoogle Scholar
  17. Hamalainen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E (2007). Anti-Inflammatory Effects of Flavonoids: Genistein, Kaempferol, Quercetin, and Daidzein Inhibit STAT-1 and NF-kB Activations, Whereas Flavone, Isorhamnetin, Naringenin, and Pelargonidin Inhibit only NF-kB Activation along with Their Inhibitory Effect on iNOS Expression and NO Production in Activated Macrophages-Volume 2007, Article ID 45673. Mediators of InflammationGoogle Scholar
  18. Hidalgo M, Martin-Santamaria S, Recio I, Sanchez-Moreno C, de Pascual-Teresa B, Rimbach G, de Pascual-Teresa S (2012) Potential anti-inflammatory, anti-adhesive, anti/estrogenic, and angiotensin-converting enzyme inhibitory activities of anthocyanins and their gut metabolites. Genes Nutr 7:295–306CrossRefPubMedPubMedCentralGoogle Scholar
  19. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L (1995) Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 108:258S–275SCrossRefPubMedGoogle Scholar
  20. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947CrossRefPubMedGoogle Scholar
  21. Kamei H, Kojima T, Hasegawa M, Koide T, Umeda T, Yukawa T, Terabe K (1995) Suppression of tumor cell growth by anthocyanins in vitro. Cancer Invest 13:590–594CrossRefPubMedGoogle Scholar
  22. Kamenickova A, Anzenbacherova E, Pavek P, Soshilov AA, Denison MS, Anzenbacher P, Dvorak Z (2013) Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T. Toxicol Lett 218:253–259CrossRefPubMedPubMedCentralGoogle Scholar
  23. Kang SY, Seeram NP, Nair MG, Bourquin LD (2003) Tart cherry anthocyanins inhibit tumor development in Apc(Min) mice and reduce proliferation of human colon cancer cells. Cancer Lett 194:13–19CrossRefPubMedGoogle Scholar
  24. Katsube N, Iwashita K, Tsushida T, Yamaki K, Kobori M (2003) Induction of apoptosis in cancer cells by Bilberry (Vaccinium myrtillus) and the anthocyanins. J Agric Food Chem 51:68–75CrossRefPubMedGoogle Scholar
  25. K-i Oyama, Kawaguchi S, Yoshida K, Kondo T (2007) Synthesis of pelargonidin 3-O-6″-O-acetyl-β-d-glucopyranoside, an acylated anthocyanin, via the corresponding kaempferol glucoside. Tetrahedron Lett 48:6005–6009CrossRefGoogle Scholar
  26. Kim TH, Ku SK, Bae JS (2012) Antithrombotic and profibrinolytic activities of eckol and dieckol. J Cell Biochem 113:2877–2883CrossRefPubMedGoogle Scholar
  27. Kong JM, Chia LS, Goh NK, Chia TF, Brouillard R (2003) Analysis and biological activities of anthocyanins. Phytochemistry 64:923–933CrossRefPubMedGoogle Scholar
  28. Ku SK, Bae JS (2014) Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo. BMB Rep 47:376–381CrossRefPubMedPubMedCentralGoogle Scholar
  29. Ku SK, Han MS, Lee MY, Lee YM, Bae JS (2014) Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Rep 47:336–341CrossRefPubMedPubMedCentralGoogle Scholar
  30. Ku SK, Lee W, Kang M, Bae JS (2015) Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa. Arch Pharm Res 38:1080–1089CrossRefPubMedGoogle Scholar
  31. Lee KH (2000) Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutr 3:515–522CrossRefPubMedGoogle Scholar
  32. Lee W, Ku SK, Bae JS (2015) Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin. Arch Pharm Res 38:893–903CrossRefPubMedGoogle Scholar
  33. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152:359–366CrossRefPubMedGoogle Scholar
  34. Marin L, Miguelez EM, Villar CJ, Lombo F (2015) Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties. Biomed Res Int 2015:905215CrossRefPubMedPubMedCentralGoogle Scholar
  35. Noda Y, Kaneyuki T, Mori A, Packer L (2002) Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin. J Agric Food Chem 50:166–171CrossRefPubMedGoogle Scholar
  36. Nowak P, Zbikowska HM, Ponczek M, Kolodziejczyk J, Wachowicz B (2007) Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb Res 121:163–174CrossRefPubMedGoogle Scholar
  37. Oldoni TLC, Melo PS, Massarioli AP, Moreno IAM, Bezerra RMN, Rosalen PL, da Silva GVJ, Nascimento AM, Alencar SM (2016) Bioassay-guided isolation of proanthocyanidins with antioxidant activity from peanut (Arachis hypogaea) skin by combination of chromatography techniques. Food Chem 192:306–312CrossRefPubMedGoogle Scholar
  38. Paredes-Lopez O, Cervantes-Ceja ML, Vigna-Perez M, Hernandez-Perez T (2010) Berries: improving human health and healthy aging, and promoting quality life–a review. Plant Foods Hum Nutr 65:299–308CrossRefPubMedGoogle Scholar
  39. Pereira MS, Melo FR, Mourao PA (2002) Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? Glycobiology 12:573–580CrossRefPubMedGoogle Scholar
  40. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, Juhan-Vague I (1995) Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 8:1352–1356CrossRefPubMedGoogle Scholar
  41. Quinn C, Hill J, Hassouna H (2000) A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 13:229–238PubMedGoogle Scholar
  42. Rao LV, Rapaport SI, Lorenzi M (1988) Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71:791–796PubMedGoogle Scholar
  43. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8:1227–1234CrossRefPubMedGoogle Scholar
  44. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263:5797–5803PubMedGoogle Scholar
  45. Schmitt E, Stopper H (2001) Estrogenic activity of naturally occurring anthocyanidins. Nutr Cancer 41:145–149CrossRefPubMedGoogle Scholar
  46. Schouten M, Wiersinga WJ, Levi M, van der Poll T (2008) Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 83:536–545CrossRefPubMedGoogle Scholar
  47. Sim D, Flaumenhaft R, Furie B (2005) Interactions of platelets, blood-borne tissue factor, and fibrin during arteriolar thrombus formation in vivo. Microcirculation 12:301–311CrossRefPubMedGoogle Scholar
  48. Sugo T, Nakamikawa C, Tanabe S, Matsuda M (1995) Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J Biochem 117:244–250CrossRefPubMedGoogle Scholar
  49. Tijburg LBM, Mattern T, Folts JD, Weisgerber UM, Katan MB (1997) Tea flavonoids and cardiovascular diseases: a review. Crit Rev Food Sci Nutr 37:771–785CrossRefPubMedGoogle Scholar
  50. Tsuda T, Horio F, Osawa T (1998) Dietary cyanidin 3-O-beta-D-glucoside increases ex vivo oxidation resistance of serum in rats. Lipids 33:583–588CrossRefPubMedGoogle Scholar
  51. Wang H, Cao G, Prior RL (1997) Oxygen radical absorbing capacity of anthocyanins. J Agric Food Chem 45:304–309CrossRefGoogle Scholar
  52. Weitz JI, Hirsh J, Samama MM (2004) New anticoagulant drugs: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:265S–286SCrossRefPubMedGoogle Scholar
  53. Wells PS, Forgie MA, Rodger MA (2014) Treatment of venous thromboembolism. JAMA 311:717–728CrossRefPubMedGoogle Scholar
  54. Zhu Z, Kuang M, Lamikanra O, Liu G, Li S, He J (2015) Preparation and toxicological evaluation of methyl pyranoanthocyanin. Food Chem Toxicology. 83:125–132CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2016

Authors and Affiliations

  • Sae-Kwang Ku
    • 1
  • Eun-Kyung Yoon
    • 2
  • Wonhwa Lee
    • 2
    • 3
  • Sinae Kwon
    • 2
  • Taeho Lee
    • 2
  • Jong-Sup Bae
    • 2
    Email author
  1. 1.Department of Anatomy and Histology, College of Korean MedicineDaegu Haany UniversityGyeongsanRepublic of Korea
  2. 2.College of Pharmacy, CMRI, Research Institute of Pharmaceutical SciencesKyungpook National UniversityDaeguRepublic of Korea
  3. 3.Department of Biochemistry and Cell Biology, BK21 Plus KNU Biomedical Convergence Program, School of MedicineKyungpook National UniversityDaeguRepublic of Korea

Personalised recommendations